ime Fitness Inc. Linkedln Corp. Major Lindsey & Africa Minnesota Twins Minnesota Vikings Motion Picture Association of America Nardello & Co. Novo Nordisk NS PNC Financial Services Group Inc. Petrobras PricewaterhouseCoopers International Ltd. Purdue Pharma LP Retail Industry Leaders Association

mith & Nephew soon at 'significant premium" (Bloomberg) • Equinix board approves REIT conversion effective for taxable year beginning Jan 1 2015 • Novo Nordisk (NOVOB DC): Saxenda wins FDA approval to treat obesity (was expected) • HeidelbergCement sells Hanson Building Products unit for $1.4B to Lone Star

nd Friday. European markets mostly higher with Spain & Italy underperforming -0.25%. Volumes tracking — 90% of 20day average. In single stock news, Novo Nordisk (NOVOB DC) trading -11.7% after the FDA denied approval of its diabetic drug. SPA's +3 handles = 1515.60 last. "'EU Fin Min meeting today & tomorro

with prelims on Oct 29 (trading -1.5%) • Lafarge reports EBITDA inline, reiterates FY demand forecast, stock has had good run (trading +0.49%) • Novo Nordisk: FDA panel votes 8-4 to approve new ultra-long-lasting insulin Degludec (trading +8.3%) • IAG reports inline with estimates but FY loss much worse

ise unenforceable promise, it will not apply where the alleged promise was bargained for as part of a contract." Id. (citing Genencor Girl, Inc. v. Novo Nordisk A/S, 766 A.2d 8, 12 (Del. 2000)). In this scenario, the applicable claim would be breach of contract, not promissory estoppel. In no instance does

cal Europe GMBH Clayton, Dubilier & Rice LLP Leighton Holdings Ltd Smith School of Enterprise and the Environment (SSEE) BUPA ZenithOptimedia Novo Nordisk A/S The Daily Beast Sero Lease and Finance (Selfina) Permanent Mission of Japan Daiwa Securities Group Inc. USA USA Saudi Arabia Saudi Arabi

, LLC NeuroPace, Inc. Neurovirtual USA, Inc. NinePoint Medical, Inc. North American Science Associates, Inc. Novartis Diagnostics NovaScan LLC Novo Nordisk, Inc. Novocure NuMED Inc NxThera, Inc. OBMedical Company• Olympus America Inc.* OPHTEC USA, Inc. Oraya Therapeutics, Inc. OrbusNeich Medical,

od Programme. See, é.¢., Complaint, SEC v. Innospec, supra note 79; Criminal Information, United States v. Innospec, supra note 79; Complaint, SEC v. Novo Nordisk A/S, No. 09-cv-862 (D.D.C. May 11, 2009), ECF No. 1, available at http://www.sec.gov/ litigation/ complaints/ 2009/comp21033. pdf; Criminal Informati